得益于呋喹替尼在海外市场快速放量,2024年公司实现盈利2024年公司总收入为6.30亿美元,其中肿瘤/免疫业务综合收入3.63亿美元,复合公司此前指引(3-4亿美元)。得益于呋喹替尼海外市场快速放量,肿瘤产品综合收入2.72亿美元(同比+65%),高于公司指引(增速30%-50%)。2024年公司净收益为0.38亿美元,实现再次盈利。基于公司核心产品呋喹替尼海外需求强劲,及2025年初出售非核心...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.